Published in BJU Int on April 03, 2014
Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol (2015) 0.83
Upper tract urothelial carcinoma: do we really need to burn down the house? BJU Int (2014) 0.75
Segmental ureteroileal conduit resection for the treatment of distal upper urinary tract recurrence of bladder cancer following cystectomy. Chin J Cancer (2016) 0.75
The role of diagnostic ureteroscopy in the era of computed tomography urography. BMC Urol (2015) 0.75
Conservative treatment of upper urinary tract carcinoma: Long-term results. Can Urol Assoc J (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology (1998) 3.81
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer (2009) 3.12
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol (2011) 2.70
Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology (2002) 2.63
Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol (2010) 1.91
Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol (2006) 1.86
Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol (2010) 1.84
Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology (2011) 1.78
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer (2010) 1.77
Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int (2008) 1.60
Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer (2009) 1.51
Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol (2010) 1.26
Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology (2010) 1.25
Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol (2007) 1.20
Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol (2000) 1.06
Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol (2009) 1.05
Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology (2006) 1.04
When is partial ureterectomy acceptable for transitional-cell carcinoma of the ureter? J Endourol (2001) 1.00
The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer (2003) 1.00
Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol (2003) 0.99
Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol (2012) 0.96
Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma. J Urol (2011) 0.93
Should partial nephrectomy be offered to all patients whenever technically feasible? Eur Urol (2011) 0.92
High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol (2012) 0.91
A national evaluation of the effect of trauma-center care on mortality. N Engl J Med (2006) 9.74
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol (2009) 6.71
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol (2006) 3.88
Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol (2008) 3.46
Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol (2009) 3.38
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol (2011) 2.87
Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg (2009) 2.79
Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer (2008) 2.75
Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol (2011) 2.51
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology (2011) 2.20
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer (2011) 1.98
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims. Stat Sci (2009) 1.92
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol (2012) 1.78
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70
Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control (2010) 1.69
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer (2008) 1.64
Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol (2012) 1.64
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60
Enhancing renal masses with zero net growth during active surveillance. J Urol (2007) 1.59
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57
Factors affecting recovery of functional status in older adults after cancer surgery. J Am Geriatr Soc (2010) 1.56
Assessing performance trends in laparoscopic nephrectomy and nephron-sparing surgery for localized renal tumors. Urology (2012) 1.54
Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol (2012) 1.53
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49
Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology (2013) 1.49
Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol (2002) 1.48
Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology (2011) 1.46
Robot-assisted partial nephrectomy: a large single-institutional experience. Urology (2010) 1.45
Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses. Can J Urol (2012) 1.45
Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol (2010) 1.44
Cancer patient preferences for quality and length of life. Cancer (2008) 1.43
Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int (2013) 1.41
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care (2015) 1.41
Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol (2013) 1.40
Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma. J Urol (2012) 1.40
The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Can J Urol (2017) 1.39
How Hugh Hampton Young's treatment of President Woodrow Wilson's urinary retention and urosepsis affected the resolution of World War I. J Urol (2011) 1.38
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer (2004) 1.38
Atomic bomb survivor cataract surgery prevalence data are consistent with non-zero threshold dose--Comment on article by Nakashima et al. 2013. Health Phys (2014) 1.38
Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol (2008) 1.37
Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) (2009) 1.36
The National Study on Costs and Outcomes of Trauma. J Trauma (2007) 1.34
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int (2011) 1.31
The impact of trauma-center care on functional outcomes following major lower-limb trauma. J Bone Joint Surg Am (2008) 1.31
Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28
Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol (2004) 1.26
Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol (2010) 1.26
Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23
Endourological management of pediatric stone disease: present status. J Urol (2008) 1.23
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22
A preliminary investigation of the predictors of tanning dependence. Am J Health Behav (2008) 1.22
Pediatric flexible ureteroscopic lithotripsy: the children's hospital of Philadelphia experience. J Urol (2008) 1.20